Scaling delivery is key for CAR T therapies to succeed in autoimmune diseases

Biopharma companies are exploring CAR T cell therapies as a potential cure for autoimmune disorders, a market that could be twice the size of oncology. While current treatments manage symptoms, they rarely achieve drug‑free remission.

All seven approved CAR T products target blood cancers, but developers see an opportunity to expand into autoimmune indications. The promise lies in the ability of engineered T cells to reset the immune system without ongoing medication.

Experts warn that reaching the broader autoimmune patient base will require significant advances in the provider ecosystem, clinical infrastructure, and patient education. Scaling manufacturing and delivery processes, as well as addressing payer concerns, are seen as critical hurdles.

If these barriers can be overcome, the CAR T market could experience substantial growth, offering a new therapeutic avenue for millions of patients with chronic autoimmune diseases.